TAK-220

CAS No. 333994-00-6

TAK-220( TAK 220 | TAK220 )

Catalog No. M14130 CAS No. 333994-00-6

A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 312 Get Quote
50MG 1341 Get Quote
100MG 1791 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TAK-220
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM.
  • Description
    A potent, specific, orally bioavailable CCR5 antagonist that blocks the binding of MIP-1α to CCR5 with IC50 of 1.4 nM; shows no affinity for CCR1, CCR2b, CCR3, CCR4, or CCR7; inhibits the replication of 6 CCR5-using (R5) HIV-1 clinical isolates in peripheral blood mononuclear cells (PBMCs) with mean EC90 of 13 nM; selectively inhibits R5 HIV-1 replication by interfering with coreceptor-mediated entry of the virus into host cells; exhibits a good pharmacokinetic profile in monkeys.HIV Infection Phase 1 Clinical.
  • In Vitro
    TAK-220 is a selective CCR5 antagonist, with IC50s of 3.5 nM and 1.4 nM for inhibition on the binding of RANTES and MIP-1α to CCR5 in CHO cells, respectively, but shows no effect on the binding to CCR1, CCR2b, CCR3, CCR4, or CCR7. TAK-220 (0-1000 nM) interacts with CCR5 but not with RANTES and inhibits the CCR5-mediated Casup>2+ signaling. TAK-220 inhibits R5 HIV-1 (JR-FL) envelope-mediated membrane fusion, with an IC50 value of 0.42 nM, but does not alter X4 HIV-1 (HXB2) envelope-mediated membrane fusion. TAK-220 also selectively inhibits HIV-1, with EC50s of 1.2 nM (HIV-1 KK), 0.72 nM (HIV-1 CTV), 1.7 nM (HIV-1 HKW), 1.7 nM (HIV-1 HNK), 0.93 nM (HIV-1 HTN), and 0.55 nM (HIV-1 HHA), and EC90s of 12 nM (HIV-1 KK), 5 nM (HIV-1 CTV), 12 nM (HIV-1 HKW), 28 nM (HIV-1 HNK), 15 nM (HIV-1 HTN), and 4 nM (HIV-1 HHA) in PBMCs. TAK-220 shows potent inhibitory activity against the R5 isolates, with IC50s of 3.12 nM against HIV-1 R5-08, 13.47 nM against HIV-1 R5-06, and 2.26 nM against HIV-1 R5-18. TAK-220 (>100 nM) has no toxicity in uninfected PBMCs.
  • In Vivo
    ——
  • Synonyms
    TAK 220 | TAK220
  • Pathway
    GPCR/G Protein
  • Target
    Chemokine Receptor
  • Recptor
    Chemokine Receptor
  • Research Area
    Infection
  • Indication
    HIV Infection

Chemical Information

  • CAS Number
    333994-00-6
  • Formula Weight
    553.1353
  • Molecular Formula
    C31H41ClN4O3
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    O=C(C1CCN(C(C)=O)CC1)N(CCCN2CCC(CC3=CC=C(C(N)=O)C=C3)CC2)C4=CC=C(C)C(Cl)=C4
  • Chemical Name
    4-Piperidinecarboxamide, 1-acetyl-N-[3-[4-[[4-(aminocarbonyl)phenyl]methyl]-1-piperidinyl]propyl]-N-(3-chloro-4-methylphenyl)-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tremblay CL, et al. Antimicrob Agents Chemother. 2005 Aug;49(8):3483-5. 2. Takashima K, et al. Antimicrob Agents Chemother. 2005 Aug;49(8):3474-82. 3. Imamura S, et al. J Med Chem. 2006 May 4;49(9):2784-93.
molnova catalog
related products
  • CCX140

    A potent, selective, orally bioavailable CCR2 antagonist with Kd of 2.3 nM for hCCR2.

  • SCH-563705

    A potent, orally bioavailable dual CXCR2/CXCR1 receptor antagonist with IC50 of 1.3 nM and 7.3 nM, respectively.

  • GW-766994 R-form

    GW-766994 (GW766994) is a potent, selective, orally available CCR3 antagonist with pKi of 7.86 for inhibiting eotaxin-induced eosinophil chemotaxis in vitro assays.